RESEARCH HIGHLIGHT
“Pediatric fatty liver disease can be much more aggressive and more difficult to treat than the adult forms of the disease. Because there are no approved treatments for pediatric MASLD and MASH, our research is focused on addressing this incredibly urgent need.”
Brian J. DeBosch, MD, PhD Co-Division Chief, Gastroenterology, Riley Children’s Health Professor of Pediatrics, IU School of Medicine > Connect with Dr. DeBosch on Doximity.
INVESTIGATORS Brian DeBosch, MD, PhD, has discovered a vital connection between the urea cycle—a crucial process for detoxifying ammonia—and the development of fatty liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Findings from his research could inform new therapies for treating fatty liver disease, a leading cause of liver failure, in children.
More about gastroenterology at Riley Children’s Riley gastroenterologists and researchers are leading clinical studies for adolescent obesity, pediatric liver disease, pediatric ulcerative colitis and other conditions. > Learn more about our program.
>
READ about the studies that resulted in publications in Cell Metabolism and Cell Reports Medicine .
rileychildrens.org
Made with FlippingBook flipbook maker